不同PD-L1检测抗体在头颈鳞癌中联合阳性评分的一致性研究

Concordance of CPS score in head and neck squamous cell carcinoma with different PD-L1 detection antibodies

目的比较22C3 pharmDx与SP263 Aassy检测头颈鳞癌标本中PD-L1联合阳性评分(CPS)的一致性。方法纳入陕西省肿瘤医院病理科诊断的55例头颈鳞癌标本进行前瞻性研究,所有标本均进行PD-L1免疫组织化学方法检测,比较两种不同抗体22C3 pharmDx与SP263 Aassy CPS的阳性检出率,分析22C3 pharmDx与SP263 Aassy检测头颈鳞癌标本PD-L1 CPS评分的一致性。结果PD-L1的表达率与患者年龄、肿瘤部位、分期和分级无相关性(P>0.05),22C3 PharmDx和SP263 Aassy两种检测方法之间的PD-L1 CPS评分结果有较强的正相关性(Spearman相关系数为0.979,P<0.01)。在CPS≥1和CPS≥20时,两种检测方法均具有较强的一致性(Cohen’s Kappa值分别为0.61和0.66)。结论22C3 pharmDx与SP263 Aassy两种抗体在头颈鳞癌中的PD-L1表达具有高度的一致性,在头颈鳞癌患者选择免疫治疗时,这两种抗体CPS的评估结果具有一定的互换性。可为头颈鳞癌的PD-L1 CPS评分提供更多可能的选择。

Objectives To assess the concordance of PD-L1 CPS scores in head and neck squamous cell carcinoma specimens using the 22C3 pharmDx and SP263 aassy.Methods A prospective study was conducted on 55 head and neck squamous cell carcinoma specimens diagnosed in the pathology department.Immunohistochemical methods were utilized to detect PD-L1 expression.The positive detection rates of PD-L1 CPS scores using the 22C3 pharmDx and SP263 aassy were compared,and the concordance of PD-L1 CPS scores between the two assays was analyzed.Results There was no significant correlation between PD-L1 expression rate and patient age,tumor location,staging,and grading(P>0.05).Strong positive correlation was observed between PD-L1 CPS scores obtained with the 22C3 pharmDx and SP263 assays(Spearman correlation coefficient=0.979,P<0.01).Both assays demonstrated high concordance in PD-L1 CPS scores when CPS cut-offs were set at≥1 and≥20(Cohen's Kappa values of 0.61 and 0.66,respectively).Conclusion The antibodies 22C3 pharmDx and SP263 exhibits high consistency in PD-L1 expression in head and neck squamous cell carcinoma.The assessment results of PD-L1 CPS using these two antibodies can be interchangeably used when selecting immune therapy for patients with head and neck squamous cell carcinoma,providing additional options for PD-L1 CPS testing.